Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.

Kwara A, Ramachandran G, Swaminathan S.

Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):55-68. doi: 10.1517/17425250903393752. Review.

2.

A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.

Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, Burapatarawong S, Thongyen S, Likanonsakul S, Thawornwa U, Prommool V, Ruxrungtham K; N2R Study Team..

Clin Infect Dis. 2009 Jun 15;48(12):1752-9. doi: 10.1086/599114.

PMID:
19438397
3.

Concomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patients.

Sathia L, Obiorah I, Taylor G, Kon O, O'Donoghue M, Gibbins S, Walsh J, Winston A.

AIDS Res Hum Retroviruses. 2008 Jul;24(7):897-901. doi: 10.1089/aid.2007.0277.

PMID:
18671475
4.

Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.

Bhatt NB, Barau C, Amin A, Baudin E, Meggi B, Silva C, Furlan V, Grinsztejn B, Barrail-Tran A, Bonnet M, Taburet AM; ANRS 12146-CARINEMO Study Group..

Antimicrob Agents Chemother. 2014 Jun;58(6):3182-90. doi: 10.1128/AAC.02379-13. Epub 2014 Mar 24.

5.

Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.

Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, Abrahams M, Goemaere E, Coetzee D, Maartens G.

JAMA. 2008 Aug 6;300(5):530-9. doi: 10.1001/jama.300.5.530.

PMID:
18677025
6.

Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa.

Cohen K, Grant A, Dandara C, McIlleron H, Pemba L, Fielding K, Charalombous S, Churchyard G, Smith P, Maartens G.

Antivir Ther. 2009;14(5):687-95.

7.

Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.

Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Ainsworth J, Pozniak A, Leen C, Bansi L, Fisher M, Orkin C, Anderson J, Johnson M, Easterbrook P, Gibbons S, Khoo S; Liverpool TDM Database.; UK CHIC Study..

Antivir Ther. 2008;13(5):675-85.

PMID:
18771051
8.

Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.

Habtewold A, Makonnen E, Amogne W, Yimer G, Aderaye G, Bertilsson L, Burhenne J, Aklillu E.

Pharmacogenomics. 2015;16(10):1047-64. doi: 10.2217/pgs.15.35. Epub 2015 Apr 1.

9.

Do we still need lead-in dosing of nevirapine in HIV-infected patients who are receiving rifampicin-containing antituberculous therapy?

Chang SY, Lin SW, Hung CC.

Clin Infect Dis. 2009 Nov 1;49(9):1452-3; author reply 1453-4. doi: 10.1086/644494. No abstract available.

PMID:
19824849
10.

Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries.

Maartens G, Decloedt E, Cohen K.

Antivir Ther. 2009;14(8):1039-43. doi: 10.3851/IMP1455. Review.

PMID:
20032533
11.

Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients.

Rajesh L, Karunaianantham R, Narayanan PR, Swaminathan S.

AIDS Res Hum Retroviruses. 2009 Nov;25(11):1179-85. doi: 10.1089/aid.2009.0110.

PMID:
19895208
12.

Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.

Mbuagbaw L, Mursleen S, Irlam JH, Spaulding AB, Rutherford GW, Siegfried N.

Cochrane Database Syst Rev. 2016 Dec 10;12:CD004246. doi: 10.1002/14651858.CD004246.pub4. Review.

PMID:
27943261
13.

Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis.

Manosuthi W, Ruxrungtham K, Likanonsakul S, Prasithsirikul W, Inthong Y, Phoorisri T, Sungkanuparph S.

Clin Infect Dis. 2007 Jan 1;44(1):141-4. Epub 2006 Nov 21.

PMID:
17143831
14.

Management of individuals requiring antiretroviral therapy and TB treatment.

Cohen K, Meintjes G.

Curr Opin HIV AIDS. 2010 Jan;5(1):61-9. doi: 10.1097/COH.0b013e3283339309. Review.

15.

Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.

Manosuthi W, Mankatitham W, Lueangniyomkul A, Chimsuntorn S, Sungkanuparph S.

HIV Med. 2008 May;9(5):294-9. doi: 10.1111/j.1468-1293.2008.00563.x.

17.

Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin.

Avihingsanon A, Manosuthi W, Kantipong P, Chuchotaworn C, Moolphate S, Sakornjun W, Gorowara M, Yamada N, Yanai H, Mitarai S, Ishikawa N, Cooper DA, Phanuphak P, Burger D, Ruxrungtham K.

Antivir Ther. 2008;13(4):529-36.

PMID:
18672531
18.

Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.

Elsherbiny D, Cohen K, Jansson B, Smith P, McIlleron H, Simonsson US.

Eur J Clin Pharmacol. 2009 Jan;65(1):71-80. doi: 10.1007/s00228-008-0481-y. Epub 2008 Aug 27.

PMID:
18751690
19.

Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.

Cohen K, van Cutsem G, Boulle A, McIlleron H, Goemaere E, Smith PJ, Maartens G.

J Antimicrob Chemother. 2008 Feb;61(2):389-93. Epub 2007 Dec 19.

PMID:
18096560
20.

Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians.

van Oosterhout JJ, Kumwenda JJ, Beadsworth M, Mateyu G, Longwe T, Burger DM, Zijlstra EE.

Antivir Ther. 2007;12(4):515-21.

PMID:
17668560

Supplemental Content

Support Center